PTU - Polskie Towarzystwo Urologiczne
list of articles:

The activity of ACHE in bladder muscle of the patients with bladder outflow obstruction
Article published in Urologia Polska 2002/55/2.


Tomasz Szydełko 1, Wojciech Apoznański 1, Zdzisław Woźniak 2, Anna Kołodziej 1, Janusz Dembowski 1, Romuald Zdrojowy 1, Tadeusz Niezgoda 1, Jarosław Kasprzak 1
1 Katedra i Klinika Urologii AM we Wrocławiu Kierownik kliniki: prof, dr hab. Jerzy Lorenz
2 Zakład Anatomii Patologicznej AM we Wrocławiu Kierownik zakładu: prof, dr hab. Jerzy Rabczyński


urinary bladder, parasympathetic system, acetylcholinesterase (ACHE)


The objective. The authors evaluated the activity of the parasympathetic system of the urinary bladder in patients with BPH, who were treated with Hryntschak method. The indirect evaluation was based on the analysis of ACHE activity in bladder muscle, a sample of which was taken during the operation from the bladder top area.
Material and method. Evaluations were made in 13 patients operated on because of BPH. The control group consisted patients with bladder cancer in whom no storage and voiding syndromes were detected before the operation and who underwent cystectomy. Samples were frozen in liquid nitrogen and then treated with mononuclear antibody against ACHE. The intensity of the reaction was assessed semiquantitativly.
Results. ACHE was found to be more active in bladder muscle of patients with BPH.
Conclusions. ACHE activity in bladder muscle may be used as a prognostic of surgical success and thus itmay serve to select patients for additional parasympathicolytic treatment.


  1. 1. Haki \\\\\\\'I\\\\\\\": Treatment for benign prostatic hyperplasia. Course book of 5th Annual European Course in Urology (AECU); 13-30.
  2. 2. Hald % Brading AE Elbadawi A, et al: Pathophysiology of the urinary bladder in obstruction and ageing. In Denis L et al 4,h International Consultation on BPH S. C. I. Paris 1998; 131-178.
  3. 3. De la Rosette J, Perachino M, Thomas D, et al.: Guidelines on Benign Prostatic Hyperplasia. EAU Guidelines.
  4. 4. Berry SJ, Coffey DS, Walsh PC, et al: The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-479.
  5. 5. Walsh PC, Retik AB, Vaughan ED, Wein AJ: Epidemiology; Etiology, Pathophysiology, and Diagnosis of Benign Prostatic Hyperplasia from Campbell\\\\\\\'s Urology 7tn ed W. B Saunders Comp. 1998 1429-1442.
  6. 6. Abrams P, Buzelin JM, Griffiths, et al: The urodynamic assessment of lower urinary tract symptoms. In Denis et al 4th International Consultation on BPH S. C\\\\\\\'. I. Paris 1998; 323-378.
  7. 7. Chute CG, Panser LA, Girman CJ el al.: The prevalence of prostatism: a population based survey of urinary symptoms J Urol 1993; 150: 85-89.
  8. 8. Girman CJ, Jacobsen SJ, Guess HA et al: Natural history of prostatism: relation among symptoms, prostate volume and peak urinary flow. J Urol 1995; 153:1510-1515.
  9. 9. Black N, Petticrew M, Ginzler M, et al.: Do doctors and pattens agree? Views of the outcome of Iranurethral resection of the prostate. Inl J Tecxhnol Assess Health Care 1991; 7:533-544.
  10. 10. Donovan JL, Kay HE, Petrs TJ el al.: Using the ICSOoL to mesure the impact of lower urinary tract symptoms on quality of life: evidence from the ICS-BPH study. International Continence Society-BPH. Br J Urol 1997; 80:712-721.
  11. 11. Walsh PC, Retik AB, Vaughan ED, Wein AJ: Physiology and Pharmacology of the Bladder and urethra from Campbell\\\\\\\'s Urology 7th ed WB Saunders Comp 1998; 870-906.
  12. 12. Boyle P, Maisonneuve P, Stcg A:Decrease in mortality from benign prostatic hypoplasia: a major unheralded health triumph. J Urol 1996; 155:176-180.


Tomasz Szydełko
Klinika Uriihigii AM pi.
1 Maja 8
50-043 Wroclaw